Cardioneuroablation significantly reduced parasympathetic and sympathetic activity at 2 years (P<0.001) and decreased both bradyarrhythmias and tachyarrhythmias (P<0.01).
Cohort (n=83)
Does cardioneuroablation provide sustained vagal denervation and reduce arrhythmias in patients with vagal paroxysmal atrial fibrillation or neurocardiogenic syncope?
Cardioneuroablation provides sustained vagal denervation up to 2 years without evidence of reinnervation, significantly reducing arrhythmias in patients with vagal AF or neurocardiogenic syncope.
p-value: p=<0.001
Background: Several disorders present reflex or persistent increase in vagal tone that may cause refractory symptoms even in a normal heart patient. Cardioneuroablation, the vagal denervation by radiofrequency ablation of the neuromyocardial interface, was developed to treat these conditions without pacemaker implantation. A theoretical limitation could be the reinnervation, that naturally grows in the first year, that could recover the vagal hyperactivity. This study aims to verify the vagal denervation degree in the chronic phase after cardioneuroablation. Additionally, it intends to investigate the arrhythmias behavior after cardioneuroablation. Methods: Prospective longitudinal study with intrapatient comparison of 83 very symptomatic cases without significant cardiopathy, submitted to cardioneuroablation, 49 (59%) male, 47.3±17 years old, having vagal paroxysmal atrial fibrillation 58 (70%) or neurocardiogenic syncope 25 (30%), New York Heart Association class0.05) suggesting that the reinnervation has halted. There was also an important reduction in all bradyarrhythmias and tachyarrhythmias pre-cardioneuroablation versus post-cardioneuroablation ( P <0.01). Conclusions: There is an important and significant vagal and sympathetic denervation after 2 years of cardioneuroablation with a significant reduction in bradyarrhythmia and tachyarrhythmia in the whole group. There were no complications.
Pachón-M et al. (Tue,) conducted a cohort in Vagal paroxysmal atrial fibrillation or neurocardiogenic syncope (n=83). Cardioneuroablation vs. Pre-cardioneuroablation (baseline) was evaluated on Heart rate variability (time and frequency domain) and arrhythmias (p=<0.001). Cardioneuroablation significantly reduced parasympathetic and sympathetic activity at 2 years (P<0.001) and decreased both bradyarrhythmias and tachyarrhythmias (P<0.01).